<SEC-DOCUMENT>0001213900-21-029958.txt : 20210528
<SEC-HEADER>0001213900-21-029958.hdr.sgml : 20210528
<ACCEPTANCE-DATETIME>20210528163300
ACCESSION NUMBER:		0001213900-21-029958
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210528
DATE AS OF CHANGE:		20210528

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38174
		FILM NUMBER:		21980848

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>ea141829-defa14a_citius.htm
<DESCRIPTION>DEFINITIVE ADDITIONAL MATERIALS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(RULE 14a-101)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proxy Statement Pursuant to Section 14(a) of
the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by the Registrant <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by a Party other than the Registrant <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary Proxy Statement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)).</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Proxy Statement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Additional Materials.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting Material Pursuant to &sect;240.14a-12.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CITIUS PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Registrant as Specified in its Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Person(s) Filing Proxy Statement,
if Other Than the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check the appropriate box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD><TD><FONT STYLE="font-size: 10pt">No fee required.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Fee computed on table below per
Exchange Act Rules 14a-6(i)(1) and 0-11.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25px">&nbsp;</TD>
    <TD STYLE="width: 32px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title of each class of securities to which transaction applies:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Aggregate number of securities to which transaction applies:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Proposed maximum aggregate value of transaction:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Total fee paid:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Fee paid previously with preliminary
materials.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Check box if any part of the fee
is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify
the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25px">&nbsp;</TD>
    <TD STYLE="width: 32px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Amount Previously Paid:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Form, Schedule or Registration Statement No.:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">Filing Party:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Date Filed:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Citius Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>11 Commerce Drive, 1st Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Cranford, NJ 07016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SUPPLEMENT TO PROXY
STATEMENT FOR SPECIAL MEETING OF STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">Citius Pharmaceuticals, Inc.,
will send to certain of its stockholders of record as of April 7, 2021 a letter related to Proposal 1 as described in the Definitive Proxy
Statement for its Special Meeting of Stockholders, to be reconvened on June 21, 2021 at 8:00 a.m. Eastern Time. A copy of the Definitive
Proxy Statement was filed with the Securities and Exchange Commission on April 12, 2021. A copy of the letter is set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>THIS SUPPLEMENT, INCLUDING
THE COPY OF THE LETTER INCLUDED BELOW, SHOULD BE READ IN CONJUNCTION WITH THE DEFINITIVE PROXY STATEMENT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><IMG SRC="image_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Citius Pharmaceuticals
Management and Board of Directors Recommend that All Stockholders<BR>
Vote &ldquo;FOR&rdquo; the Increase in Authorized Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Dear Fellow Stockholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The purpose of this letter is to urge stockholders
who have not yet voted on the proxy proposal to increase the number of Citius Pharmaceutical, Inc. authorized shares to please vote &ldquo;FOR&rdquo;
the proposal immediately. Your vote is critically important to the future of Citius. &nbsp;If you previously voted &ldquo;FOR&rdquo; the
proposal, no further action is needed. If you previously voted &ldquo;AGAINST&quot; the proposal or to &ldquo;ABSTAIN,&rdquo; we urge
you to change your vote now to &ldquo;FOR&rdquo; the proposal, following the enclosed voting instructions. &nbsp;The adjournment of our
special meeting to June 21, 2021 provides additional time for us to secure the votes needed to pass this proposal.&nbsp;To ensure your
vote is counted before the meeting, we strongly encourage you to vote online.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The required threshold for this proposal is
a majority of shares outstanding as of the record date. &nbsp;As of May 26, 2021, votes representing approximately 53.1% of the shares
outstanding as of the record date had been cast, with 78.9% of the shares actually voted in support of the proposal.&nbsp; However, this
represented only 41.9% of total shares outstanding as of the record date. In order for the proposal to pass, we needed approximately 11
million additional &ldquo;FOR&rdquo; votes to meet the majority of total shares outstanding threshold.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We believe that the availability of additional
authorized shares of common stock will provide us with the flexibility necessary to issue common stock for a variety of general corporate
purposes as the Company may determine to be desirable including, without limitation, raising capital, future financings, investment opportunities,
licensing agreements or acquisitions. With our bold entry into cellular medicine, we believe the flexibility in our financial resources
will be integral to optimizing our interests and building long-term shareholder value. Currently, we have approximately eight million
authorized shares that remain available for issuance, which we believe will be insufficient to provide that flexibility. While we continue
to believe our current cash and cash equivalents are sufficient to fund our operations into the first quarter of 2023, we believe pursuing
the authorized shares increase now represents a prudent and appropriate strategic decision to further fuel the growth of the Company.&nbsp;
The Board has not authorized the Company to take any action with respect to the shares that would be authorized under this proposal, and
the Company currently does not have any definitive plans, arrangements or understandings with respect to the issuance of the additional
shares of common stock authorized by the Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company has retained a proxy solicitor
to assist in the solicitation of proxies and provide related advice and informational support. &nbsp;If you would like to discuss the
proposal or have any questions regarding how to vote, you may contact Christopher Rice of Morrow Sodali LLC by phone at (203) 561 - 6945
or by email at&nbsp;c.rice@morrowsodali.com. Included with this letter are voting instructions containing your control number. We strongly
encourage you to vote &ldquo;FOR&rdquo; Proposal 1 by casting your vote online at www.ProxyVote.com prior to June 21, 2021 so that it
may be counted before the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Thank you for your support of Citius Pharmaceuticals,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Sincerely,<BR>
Myron Holubiak<BR>
President and CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations for Citius Pharmaceuticals:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Andrew Scott</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vice President, Special Projects</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: 908-967-6677 x105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">E: ascott@citiuspharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ilanit Allen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vice President, Corporate Communications and Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: 908-967-6677 x113</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">E: iallen@citiuspharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">2</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ 2P# 2(  A$! Q$!_\0
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M[=;W/<M;.= U$C_GUE_]!->/?#V^CTW7+N]F5VCALI'81C+$ KT%>AZ/J?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
